Immunovant, Inc. Securities Litigation

If you purchased a significant amount of shares of Immunovant Inc. Common Stock (NASDAQ: IMVT), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Immunovant Inc. Common Stock
Date Filed:February 19th, 2021
Sector:Health Care
Industry:Biotechnology: Biological Products (No Diagnostic Substances)
Class Start Date:October 2nd, 2019
Class End Date:February 1st, 2021

According to the Complaint, Immunovant, Inc. is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of autoimmune diseases. On September 29, 2019, Health Sciences Acquisitions Corporation ("HSAC"), then a blank check company, or SPAC, entered into an agreement with Legacy Immunovant, a private biopharmaceutical company, and shareholders of Legacy Immunovant, to effect a merger between the two entities. As a result of the Merger, HSAC acquired all of the issued and outstanding shares of Legacy Immunovant, and Legacy Immunovant became a wholly owned subsidiary of HSAC. Upon the closing of the Merger, HSAC changed its name to "Immunovant, Inc."

Immunovant is developing IMVT-1401, a novel fully human monoclonal antibody, which is in Phase IIa clinical trials for the treatment of MG and TED, also known as Graves' ophthalmopathy. The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of WAIHA.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (ii) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (iii) the foregoing foreseeably diminished IMVT-1401's prospects for regulatory approval, commercial viability, and profitability; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Immunovant Inc. Common Stock

 
First Identified Complaint

Theresa Pitman, et al. v. Immunovant, Inc., et al.

Date Filed:February 19th, 2021
Class Period Start:October 2nd, 2019
Class Period End:February 1st, 2021
First Identified Complaint Filings
#Document TitleFiling Date